Detect Home

Detect™ Covid-19 Starter Kit

Everything you need to run your first Detect™ test. Includes the Detect™ Covid-19 Test and a reusable Detect™ Hub.

  • HSA/FSA-eligible
  • Suitable for ages 2+ years
  • Results in 1 hour
  • 24/7 support

Notify me when this product is available:

Ordering tests for your business, school, or other organization? Talk to us.

24/7 Support

We’re here to help.
Give us a call at +1 (855) 322‑3692 or email us at

Detect™ Covid-19 Test

Already have a Detect™ Hub? Order a new Detect™ Covid-19 Test. For those who already have a Detect™ Hub.

Learn More

Detect™ Hub

Additional or replacement Detect™ Hub for your Detect™ Covid-19 Tests. The Detect™ Hub is reusable and required to complete the processing step for any Detect™ test.

Learn More

For your organization

Learn More
Why Detect™

Clinically studied and validated

Shown to be on par with expensive PCR lab tests in FDA-reviewed clinical studies.



Across our clinical studies, our test is comparable to PCR tests.



We correctly identified positive samples 90.9% of the time in clinical studies.



We correctly identified negative samples 100% of the time in clinical studies.

<1 copy/µL

Limit of Detection

Our Limit of Detection is 313 copies/swab (<1 copy/µL) in analytical studies, which is on par with widely used PCR lab tests.

A clinical study was conducted across two sites, with testing performed by untrained operators. The study enrolled symptomatic subjects and subjects with recent Covid-19 exposure, each of whom self-collected two nasal swab samples (adults) or had two nasal swab samples collected by an adult caregiver (children under 14). For each subject, one swab was collected and sent to a reference laboratory and tested using a high sensitivity FDA-authorized SARS-CoV-2 RT-PCR test by trained laboratory personnel as a comparator, while the other swab was tested using the Detect Covid-19 Test by the untrained subject or caregiver at the clinical site. Comparing the Detect Covid-19 Test’s results to those produced by the high sensitivity FDA-authorized SARS-CoV-2 RT-PCR test, the Positive Percent Agreement (PPA) was 90.9% (30/33) and the Negative Percent Agreement (NPA) was 100% (79/79) with expert interpretation.